Targeting SIRT3 to Ameliorate Diabetic Cardiomyopathy: Progress in Mechanistic Research and Prospects for Clinical Translation.

Diabetes mellitus (DM) is one of the most common chronic diseases worldwide, and diabetic cardiomyopathy (DCM) is one of the cardiovascular complications of DM, described as the development of abnormalities of myocardial structure/function associated with DM in the absence of coronary artery disease, hypertension, and valvular disease. The disease has an insidious onset and lacks effective treatment. Studies have shown that even with effective glycemic control, the progression of DCM cannot be prevented. Exploring the pathogenesis of DCM and identifying effective intervention targets is the focus and hotspot of current research. Silent message regulator 3 (Sirtuin3, SIRT3) is one of the members of the nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase family of sirtuins, and studies have confirmed that SIRT3 has a protective effect on cardiovascular disease and may become a new target for the treatment of cardiovascular diseases. Therefore, this paper emphasizes the role of SIRT3 in DCM, describes the mechanism of SIRT3 in DCM, and summarizes the methods to improve DCM by elevating the level of SIRT3, aiming to provide new perspectives for treating and delaying DCM.